Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results

Avi I. Einzig*, Stuart Lipsitz, Peter H. Wiernik, Al B Benson III

*Corresponding author for this work

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.

Original languageEnglish (US)
Pages (from-to)223-227
Number of pages5
JournalInvestigational New Drugs
Volume13
Issue number3
DOIs
StatePublished - Sep 1 1995

Fingerprint

Upper Gastrointestinal Tract
Paclitaxel
Adenocarcinoma
Neutropenia
Neoplasm Metastasis
Liver

Keywords

  • Taxol (paclitaxel)
  • upper gastrointestinal tumors

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Pharmacology (medical)

Cite this

@article{cd880a75782d49c0b227b10da635d00a,
title = "Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results",
abstract = "Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5{\%}) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.",
keywords = "Taxol (paclitaxel), upper gastrointestinal tumors",
author = "Einzig, {Avi I.} and Stuart Lipsitz and Wiernik, {Peter H.} and {Benson III}, {Al B}",
year = "1995",
month = "9",
day = "1",
doi = "10.1007/BF00873804",
language = "English (US)",
volume = "13",
pages = "223--227",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results. / Einzig, Avi I.; Lipsitz, Stuart; Wiernik, Peter H.; Benson III, Al B.

In: Investigational New Drugs, Vol. 13, No. 3, 01.09.1995, p. 223-227.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Phase II trial of taxol in patients with adenocarcinoma of the upper gastrointestinal tract (UGIT) - The Eastern Cooperative Oncology Group (ECOG) Results

AU - Einzig, Avi I.

AU - Lipsitz, Stuart

AU - Wiernik, Peter H.

AU - Benson III, Al B

PY - 1995/9/1

Y1 - 1995/9/1

N2 - Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.

AB - Taxol was administered as a 24-hour continuous infusion at 250 mg/m2 in this Phase II trial in patients with adenocarcinomas of the upper gastrointestinal tract (UGIT). Twenty-five patients were entered between July 1991 and June 1992, twenty-three were eligible and were evaluated for toxicity and twenty-two were assessable for response. There was one partial response (4.5%) in a patient with liver metastases, with a duration of 6 months. Toxicity was primarily neutropenia. Taxol as a single agent appears to have little activity in adenocarcinoma of the UGIT.

KW - Taxol (paclitaxel)

KW - upper gastrointestinal tumors

UR - http://www.scopus.com/inward/record.url?scp=0029550022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029550022&partnerID=8YFLogxK

U2 - 10.1007/BF00873804

DO - 10.1007/BF00873804

M3 - Article

C2 - 8729950

AN - SCOPUS:0029550022

VL - 13

SP - 223

EP - 227

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 3

ER -